BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- via BioMedWire -- IBN (“InvestorBrandNetwork”), an innovative content distributor and multifaceted communications organization with 50+ brands including BioMedWire (“BMW”), is pleased to announce that it will be collaborating with Hanson Wade as an official media sponsor for the upcoming 2nd Annual Gene Therapy Patient Engagement Summit, which is set to be held in Boston, MA, June 7-9th, 2022.
In the rapidly growing field of gene therapy, companies and institutions believe that creating patient-centric gene therapy programs is eminent to successful development. The 2nd Annual Gene Therapy Patient Engagement Summit unites patient advocacy groups, engagement leaders and the patients themselves to provide insight and honest discussions.
During the three-day event, presentations will be held on a variety of topics, including how to manage expectations of gene therapy across stakeholders, incorporating the latest regulatory guidelines on patient input, designing and implementing meaningful clinical trials, tackling education and misconceptions in gene therapy and engaging in early development with patient groups. Presenters will include the likes of Spark Therapeutics, Ultragenyx, FDA, Global Genes and CRISPR Therapeutics.
Separately, and in addition to the coverage provided by Hanson Wade and BioMedWire, IBN is set to provide social media coverage of the event. Collectively among its 50+ brands, IBN reaches more than 2 million likes and followers across various social networking platforms.
“Our team is excited to be working with Hanson Wade as we raise the visibility of the 2nd Annual Gene Therapy Patient Engagement Summit,” said Jonathan Keim, Director of Communications. “Hanson Wade has gained a well-deserved reputation as an informational leader in the space. We look forward to featuring the innovations taking place in gene therapy programs where the patient’s experience and voice are vital to the industry’s advancements.”
For additional details about the 2nd Annual Gene Therapy Patient Engagement Summit, visit https://genetherapy-patient-engagement.com
About IBN
IBN (“InvestorBrandNetwork”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.
For more information on IBN, visit https://www.InvestorBrandNetwork.com.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN wherever published or republished: https://IBN.fm/Disclaimer
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
